While precision medicine has focused on tumor biology, this research suggests a broader "precision care" approach is needed. This involves tailoring treatment, such as drug dosage, based on patient-specific factors like physiology, functional reserve, and personal goals, not just genomic markers.

A blinded central radiology review is not the absolute gold standard for assessing patient progression. Expert clinicians argue their holistic assessment, incorporating the patient's clinical status and other biomarkers alongside scans, provides critical context that a disconnected reviewer lacks.

The modern practice of waiting for detailed diagnostic and genetic information before starting AML therapy provides a crucial, previously unavailable window of time for clinicians to conduct thorough fitness and geriatric assessments on their older patients.

For frail elderly patients with HER2+ gastric cancer, starting with targeted therapy and immunotherapy alone can gauge response and tolerance. Cytotoxic chemotherapy can be added later if the patient's performance status improves, distinguishing disease-related frailty from baseline comorbidities.

When treating elderly patients (e.g., age 80+) with metastatic breast cancer, clinicians may prioritize quality of life over marginal overall survival gains seen in clinical trials. This justifies using a better-tolerated CDK4/6 inhibitor like palbociclib, even though ribociclib has demonstrated a statistical survival benefit, especially when patients have comorbidities or a preference for fewer side effects.

The physical separation of oncology specialists creates significant logistical hurdles to coordinated, multi-modal treatment. This discoordination can lead to suboptimal care, such as patients receiving neoadjuvant therapy without ever consulting a surgeon, highlighting a systemic flaw in care delivery.

The RSClin tool integrates a patient's Oncotype DX score with their unique clinical-pathologic features, such as tumor size and grade. This provides a more accurate and personalized risk assessment, as the same genomic score can represent significantly different prognoses for patients who have low versus high clinical risk factors.

Traditional age cutoffs for AML therapy are becoming obsolete. A comprehensive fitness assessment, not just chronological age, should guide treatment, as some guidelines now classify patients as young as 55 as "older adults," a surprising shift for many clinicians.

Contrary to assumptions that patients avoid difficult news, SCLC patients explicitly want to discuss prognosis. Knowing the treatment's intent—whether curative or palliative—helps them mentally prepare for toxicity, remain motivated during difficult regimens, and engage in crucial end-of-life planning with their doctors.